We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
SMMT shares rise 24% in three months, driven by ivonescimab progress and investor confidence.
The FDA accepted Summit Therapeutics' BLA for ivonescimab in NSCLC with a decision date in November 2026.
SMMT strengthened its pipeline via GSK collaboration and ongoing late-stage studies across cancers.
Shares of Summit Therapeutics (SMMT - Free Report) have rallied 24% over the past three months, driven by accelerating clinical momentum, financial strength and growing investor confidence in ivonescimab, its lead cancer therapy. The candidate has demonstrated encouraging clinical data and is increasingly viewed as a potential competitor to established cancer therapies. SMMT is developing ivonescimab in collaboration with China-based Akeso. Ivonescimab is currently approved only in China for two distinct NSCLC indications.
FDA Accepted Ivonescimab BLA for NSCLC
The primary catalyst behind the stock rally is the FDA acceptance of SMMT’s biologics license application (BLA) in January, seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with third-generation EGFR-TKIs. The regulatory body has set a target action date of Nov. 14, 2026.
The FDA plans to conduct a comprehensive review of the application, including mid-cycle and late-cycle meetings. If no major issues arise, labeling discussions may take place prior to the PDUFA action date.
The BLA submission was based on data from the phase III HARMONi study evaluating ivonescimab plus platinum-doublet chemotherapy versus placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC post EGFR-TKI therapy. The primary endpoints were progression-free survival (PFS) and overall survival (OS).
The study demonstrated a statistically significant and clinically meaningful improvement in PFS. Although it did not reach statistical significance at the time of analysis, treatment with ivonescimab plus platinum-doublet chemotherapy showed a favorable trend toward OS.
Year to date, shares of Summit have risen 20.8% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
SMMT’s Collaboration With GSK
In January 2026, Summit announced a collaboration with GSK plc (GSK - Free Report) to evaluate ivonescimab in combination with risvutatug rezetecan, GSK’s novel investigational B7-H3-targeting antibody drug conjugate, across multiple solid tumor settings, including small cell lung cancer. Each company will retain full rights to its respective products. Patient dosing is expected to commence in mid-2026.
SMMT’s Other Pipeline Progress
The company is currently enrolling patients in three late-stage studies on ivonescimab — two in NSCLC (HARMONi-3 and HARMONi-7) and one in CRC (HARMONi-GI3).
HARMONi-3 is evaluating the candidate against Merck’s (MRK - Free Report) blockbuster PD-L1 drug Keytruda (pembrolizumab) as a first-line treatment for metastatic squamous or non-squamous NSCLC, while HARMONi-7 is evaluating ivonescimab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Patient enrollment in the phase III HARMONi-GI3 study, evaluating the candidate in combination with chemotherapy against bevacizumab plus chemotherapy in first-line unresectable metastatic colorectal cancer, is ongoing.
Strong Balance Sheet
Another key factor supporting the stock’s performance is Summit Therapeutics’ strong balance sheet. As of Dec. 31, 2025, the company had cash, cash equivalents and short-term investments totaling $713.4 million with no debt.
With a substantial cash position and minimal financial risk, the company is well-positioned to fund ongoing clinical studies and potential commercialization efforts without near-term dilution risk.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. Over the same period, EPS estimates for 2027 have surged from $2.85 to $3.25. CPRX shares have gained 10.8% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Key Takeaways
Shares of Summit Therapeutics (SMMT - Free Report) have rallied 24% over the past three months, driven by accelerating clinical momentum, financial strength and growing investor confidence in ivonescimab, its lead cancer therapy. The candidate has demonstrated encouraging clinical data and is increasingly viewed as a potential competitor to established cancer therapies. SMMT is developing ivonescimab in collaboration with China-based Akeso. Ivonescimab is currently approved only in China for two distinct NSCLC indications.
FDA Accepted Ivonescimab BLA for NSCLC
The primary catalyst behind the stock rally is the FDA acceptance of SMMT’s biologics license application (BLA) in January, seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with third-generation EGFR-TKIs. The regulatory body has set a target action date of Nov. 14, 2026.
The FDA plans to conduct a comprehensive review of the application, including mid-cycle and late-cycle meetings. If no major issues arise, labeling discussions may take place prior to the PDUFA action date.
The BLA submission was based on data from the phase III HARMONi study evaluating ivonescimab plus platinum-doublet chemotherapy versus placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC post EGFR-TKI therapy. The primary endpoints were progression-free survival (PFS) and overall survival (OS).
The study demonstrated a statistically significant and clinically meaningful improvement in PFS. Although it did not reach statistical significance at the time of analysis, treatment with ivonescimab plus platinum-doublet chemotherapy showed a favorable trend toward OS.
Year to date, shares of Summit have risen 20.8% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
SMMT’s Collaboration With GSK
In January 2026, Summit announced a collaboration with GSK plc (GSK - Free Report) to evaluate ivonescimab in combination with risvutatug rezetecan, GSK’s novel investigational B7-H3-targeting antibody drug conjugate, across multiple solid tumor settings, including small cell lung cancer. Each company will retain full rights to its respective products. Patient dosing is expected to commence in mid-2026.
SMMT’s Other Pipeline Progress
The company is currently enrolling patients in three late-stage studies on ivonescimab — two in NSCLC (HARMONi-3 and HARMONi-7) and one in CRC (HARMONi-GI3).
HARMONi-3 is evaluating the candidate against Merck’s (MRK - Free Report) blockbuster PD-L1 drug Keytruda (pembrolizumab) as a first-line treatment for metastatic squamous or non-squamous NSCLC, while HARMONi-7 is evaluating ivonescimab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Patient enrollment in the phase III HARMONi-GI3 study, evaluating the candidate in combination with chemotherapy against bevacizumab plus chemotherapy in first-line unresectable metastatic colorectal cancer, is ongoing.
Strong Balance Sheet
Another key factor supporting the stock’s performance is Summit Therapeutics’ strong balance sheet. As of Dec. 31, 2025, the company had cash, cash equivalents and short-term investments totaling $713.4 million with no debt.
With a substantial cash position and minimal financial risk, the company is well-positioned to fund ongoing clinical studies and potential commercialization efforts without near-term dilution risk.
Summit Therapeutics PLC Price and Consensus
Summit Therapeutics PLC price-consensus-chart | Summit Therapeutics PLC Quote
SMMT’s Zacks Rank and Stock to Consider
Summit Therapeutics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Catalyst Pharmaceuticals (CPRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. Over the same period, EPS estimates for 2027 have surged from $2.85 to $3.25. CPRX shares have gained 10.8% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.